

# Christian Chabannon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4193997/publications.pdf>

Version: 2024-02-01

112  
papers

5,414  
citations

109321

35  
h-index

91884

69  
g-index

123  
all docs

123  
docs citations

123  
times ranked

7287  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. <i>Haematologica</i> , 2022, 107, 1054-1063.	3.5	20
2	Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2022, 57, 125-127.	2.4	6
3	Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis. <i>Bone Marrow Transplantation</i> , 2022, 57, 17-22.	2.4	5
4	Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 299-301.	2.4	8
5	Mother Donors Improve Outcomes after HLA Haploidentical Transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 206.e1-206.e6.	1.2	2
6	Betibeglogene Autotemcel Gene Therapy for Non- $\beta^0/\beta^0$ Genotype $\beta^2$ -Thalassemia. <i>New England Journal of Medicine</i> , 2022, 386, 415-427.	27.0	91
7	Structure of and Signalling Through Chimeric Antigen Receptor. , 2022, , 3-5.		4
8	The first steps towards a diverse and inclusive EBMT: a position paper. <i>Bone Marrow Transplantation</i> , 2022, 57, 343-346.	2.4	2
9	Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). <i>Annals of Oncology</i> , 2022, 33, 259-275.	1.2	139
10	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. <i>Bone Marrow Transplantation</i> , 2022, 57, 742-752.	2.4	45
11	Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia. <i>Stem Cells Translational Medicine</i> , 2022, 11, 407-414.	3.3	6
12	Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 455-462.	1.2	2
13	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. <i>Cancers</i> , 2022, 14, 2275.	3.7	0
14	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	2.4	119
15	Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. <i>Leukemia</i> , 2021, 35, 585-594.	7.2	18
16	Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products. <i>Cytotherapy</i> , 2021, 23, 77-87.	0.7	8
17	Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. <i>Bone Marrow Transplantation</i> , 2021, 56, 883-889.	2.4	10
18	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. <i>Bone Marrow Transplantation</i> , 2021, 56, 1651-1664.	2.4	221

#	ARTICLE	IF	CITATIONS
19	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1900-1907.	2.4	18
20	Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic. <i>Bone Marrow Transplantation</i> , 2021, 56, 2013-2015.	2.4	7
21	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. <i>Genome Medicine</i> , 2021, 13, 87.	8.2	24
22	Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. <i>Cancers</i> , 2021, 13, 2673.	3.7	12
23	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTAS): an international, multicentre, observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e355-e364.	4.6	43
24	Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2021, 56, 2497-2509.	2.4	6
25	Impact of the human leucocyte antigen (HLA)â€B leader peptide dimorphism and HLAâ€A expression on outcomes of stem cell transplantation for sickle cell disease. <i>British Journal of Haematology</i> , 2021, 195, e128-e131.	2.5	1
26	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 271.	3.7	39
27	Use of the HLA-B leader to optimize cord blood transplantation. <i>Haematologica</i> , 2021, 106, 3107-3114.	3.5	12
28	Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	0
29	Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 349-355.	2.4	18
30	Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. <i>Bone Marrow Transplantation</i> , 2020, 55, 613-622.	2.4	15
31	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	2.4	39
32	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e50-e60.	4.6	53
33	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	3.5	230
34	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2299-2305.	2.0	4
35	Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriersâ€”On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2098-2104.	2.0	9
36	Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life. <i>Current Opinion in Oncology</i> , 2020, 32, 427-433.	2.4	13

#	ARTICLE	IF	CITATIONS
37	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. <i>Bone Marrow Transplantation</i> , 2020, 55, 2071-2076.	2.4	163
38	Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF. <i>PLoS ONE</i> , 2020, 15, e0228878.	2.5	4
39	Welcome to ISCT 2020 Paris Virtual. <i>Cytotherapy</i> , 2020, 22, S3.	0.7	0
40	Identification of hurdles in the development of cell-based therapies. <i>Cytotherapy</i> , 2020, 22, 53-56.	0.7	1
41	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Ts come into focus. <i>Bone Marrow Transplantation</i> , 2020, 55, 1604-1613.	2.4	147
42	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	2.4	17
43	Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 1242-1249.	5.2	21
44	The connected worlds of stem cell transplantation and HIV. <i>Lancet HIV</i> , 2020, 7, e594-e595.	4.7	0
45	Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. <i>ESMO Open</i> , 2020, 5, e000860.	4.5	1
46	Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 <sup>+</sup> cells. <i>British Journal of Haematology</i> , 2019, 185, 570-573.	2.5	17
47	Development of adaptive immune effector therapies in solid tumors. <i>Annals of Oncology</i> , 2019, 30, 1740-1750.	1.2	35
48	Validation of a semi automatic device to standardize quantification of Colony-Forming Unit (CFU) on hematopoietic stem cell products. <i>Cytotherapy</i> , 2019, 21, 820-823.	0.7	8
49	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. <i>Clinical Epigenetics</i> , 2019, 11, 141.	4.1	11
50	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	7.2	47
51	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , 2019, 6, e573-e584.	4.6	140
52	A matched-pair analysis reveals marginally reduced CD34 <sup>+</sup> cell mobilization on second occasion in 27 related donors who underwent peripheral blood stem cell collection twice at the same institution. <i>Transfusion</i> , 2019, 59, 3442-3447.	1.6	4
53	The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2019, 54, 1164-1167.	2.4	7
54	Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1810-1817.	2.0	15

#	ARTICLE	IF	CITATIONS
55	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	2.4	86
56	Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. Bone Marrow Transplantation, 2019, 54, 1730-1737.	2.4	19
57	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplantation, 2019, 54, 1525-1552.	2.4	218
58	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplantation, 2019, 54, 1575-1585.	2.4	129
59	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
60	Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. Bone Marrow Transplantation, 2019, 54, 1067-1076.	2.4	20
61	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. Bone Marrow Transplantation, 2019, 54, 867-876.	2.4	8
62	HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. Biology of Blood and Marrow Transplantation, 2018, 24, 1449-1454.	2.0	39
63	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transplantation, 2018, 53, 1201-1205.	2.4	10
64	Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations. Current Research in Translational Medicine, 2018, 66, 59-61.	1.8	7
65	Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. Science Translational Medicine, 2018, 10, .	12.4	125
66	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2018, 53, 722-728.	2.4	5
67	Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. Bone Marrow Transplantation, 2018, 53, 366-370.	2.4	3
68	Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis. Bone Marrow Transplantation, 2018, 53, 246-254.	2.4	31
69	From clinical proof-of-concept to commercialization of CAR T cells. Drug Discovery Today, 2018, 23, 758-762.	6.4	17
70	Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. Bone Marrow Transplantation, 2018, 53, 1096-1104.	2.4	18
71	Killer Cell Immunoglobulin-Like Receptor – Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell – Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, 549-554.	2.0	35
72	T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 627-632.	2.0	46

#	ARTICLE	IF	CITATIONS
73	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2365-2370.	2.0	61
74	Prise en charge des cellules CAR-T au sein des établissements de santé français : fabrication, distribution, et aspects réglementaires. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 1431-1440.	0.0	1
75	Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017, 52, 683-688.	2.4	42
76	Impact of CD34-positive cell dose on outcome after peripheral blood stem cell allogeneic transplantation prepared with ATG-based reduced intensity conditioning regimen. <i>American Journal of Hematology</i> , 2017, 92, E57-E59.	4.1	4
77	JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. <i>Bone Marrow Transplantation</i> , 2017, 52, 1367-1371.	2.4	61
78	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. <i>Bone Marrow Transplantation</i> , 2017, 52, 620-621.	2.4	23
79	Jon van Rood (1926-2017). <i>Bone Marrow Transplantation</i> , 2017, 52, 1587-1587.	2.4	1
80	CAR-T cells: the narrow path between hope and bankruptcy?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1588-1589.	2.4	24
81	Low incidence of chronic <scv>GVHD</scv> after <scv>HLA</scv>-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patients. <i>British Journal of Haematology</i> , 2017, 176, 132-135.	2.5	17
82	Manufacturing Natural Killer Cells as Medicinal Products. <i>Frontiers in Immunology</i> , 2016, 7, 504.	4.8	30
83	Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 1082-1086.	2.4	13
84	New developments in the use of apheresis to collect haematopoietic cells for cell transplantation and cell therapies. <i>ISBT Science Series</i> , 2016, 11, 100-104.	1.1	2
85	Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. <i>Blood</i> , 2016, 128, 253-264.	1.4	320
86	Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous hematopoietic stem cell transplantation. <i>European Journal of Cancer</i> , 2016, 57, 118-126.	2.8	5
87	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2016, 51, 194-198.	2.4	22
88	Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. <i>Bone Marrow Transplantation</i> , 2016, 51, 319-321.	2.4	32
89	Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor. <i>Biology of Blood and Marrow Transplantation</i> . 2016. 22. 119-124.	2.0	86
90	Access to human tissues for research and product development. <i>EMBO Reports</i> , 2015, 16, 557-562.	4.5	28

#	ARTICLE	IF	CITATIONS
91	A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "demand" scheme of administration at French autologous hematopoietic stem cell transplant programs. <i>Transfusion</i> , 2015, 55, 2149-2157.	1.6	22
92	Banking or Bankrupting: Strategies for Sustaining the Economic Future of Public Cord Blood Banks. <i>PLoS ONE</i> , 2015, 10, e0143440.	2.5	34
93	Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2175-2182.	0.9	150
94	Regulation of advanced therapy medicinal products will affect the practice of haematopoietic SCT in the near future: a perspective from the EBMT cell-processing committee. <i>Bone Marrow Transplantation</i> , 2015, 50, 321-323.	2.4	10
95	PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia. <i>Leukemia</i> , 2015, 29, 1202-1206.	7.2	8
96	Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 429-439.	2.0	55
97	Cord blood collection and banking from a population with highly diverse geographic origins increase HLA diversity in the registry and do not lower the proportion of validated cord blood units: experience of the Marseille cord blood bank. <i>Bone Marrow Transplantation</i> , 2015, 50, 531-535.	2.4	1
98	Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 908-915.	3.5	83
99	Automated washing of autologous hematopoietic stem cell grafts after thawing does not impair engraftment. <i>Bone Marrow Transplantation</i> , 2014, 49, 1127-1128.	2.4	11
100	Assessing the HLA diversity of cord blood units collected from a birth clinic caring for pregnant women in an ethnically diverse metropolitan area. <i>Transfusion</i> , 2014, 54, 1046-1054.	1.6	5
101	Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 724-729.	2.0	141
102	Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 865-872.	2.4	151
103	A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. <i>American Journal of Hematology</i> , 2014, 89, 83-87.	4.1	25
104	CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 382-386.	2.0	74
105	Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 370-374.	2.0	40
106	Increase the quality of banked cord blood units without limiting HLA diversity: how cord blood banks could face this dilemma. <i>Transfusion</i> , 2014, 54, 495-496.	1.6	2
107	Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation. <i>Cancer</i> , 2013, 119, 602-611.	4.1	70
108	Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. <i>Haematologica</i> , 2012, 97, 1073-1079.	3.5	108

#	ARTICLE	IF	CITATIONS
109	Targeting natural killer cells and natural killer T cells in cancer. <i>Nature Reviews Immunology</i> , 2012, 12, 239-252.	22.7	707
110	Introduction of a Quality Management System and Outcome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2011, 29, 1980-1986.	1.6	85
111	Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. <i>Leukemia</i> , 2003, 17, 811-813.	7.2	22
112	CD34+ immunoselected cells for poor graft function following allogeneic BMT. <i>Cytotherapy</i> , 2000, 2, 367-370.	0.7	14